艾塞那肽联合甘精胰岛素治疗肥胖2型糖尿病临床观察被引量：4

Efficacy of exenatide combined with insulin glargine in newly diagnosed type 2 diabetes patients with obesity

导出

摘要目的探讨短期艾塞那肽联合甘精胰岛素治疗新诊断肥胖2型糖尿病(T2DM)的临床疗效。方法对30例新诊断但未治疗的肥胖T2DM患者给予艾塞那肽联合甘精胰岛素治疗24周,采用自身前后对照的方法,观察患者血糖、糖化血红蛋白(HbAlc)、C肽、血压、血脂及体重指数(BMI)等指标的变化情况。结果治疗后空腹血糖(FPG)、餐后2h血糖(2hPG)、HbAlc、BMI、收缩压(SBP)、甘油三酯(TG)、胆固醇(TC)和低密度脂蛋白(LDL-C)水平均显著下降,而空腹C肽(F-CP)、2hC肽(2h-CP)明显高于治疗前(P<0.01)。结论艾塞那肽联合甘精胰岛素可有效控制新诊断肥胖T2DM患者的血糖水平,改善胰岛β细胞功能,降低体重。 Objective To investigate the clinical efficacy of exenatide combined with insulin glargine in newly diagnosed type 2 diabetes patients with obesity. Methods 30 cases of newly diagnosed T2DM patients with obesity were treated with exenatide and insulin glargine for 24 weeks. Self-control study was used to evaluate the changes in blood glucose,glycosylated hemoglobin （HbAlc）, C peptide, blood pressure, lipids and body mass index （BMI）. Results Levels of fasting plasma glucose （FPG）, postprandial 2h plasma glucose （2hPG）, HbAlc, BMI, systolic blood pressure （SBP）, triglycerides （TG）, total cholesterol （TC） and low density lipoprotein cholesterol （LDL-C） were significantly decreased. On the other hand, the fasting C-peptide （F-CP）, 2h postprandial C-peptide （2h-CP） was increased obviously （P〈0.01）. Conclusion The therapy with exenatide and insulin glargine insulin could effectively control blood glucose,significantly improve β-cell functionin and reduce weight in newly diagnosed T2DM patients with obesity.

作者丁韶峰杨星林孙凤娟

机构地区济南大学山东省医学科学院医学与生命科学学院济宁医学院附属济宁市第一人民医院

出处《济宁医学院学报》 2013年第1期31-33,共3页 Journal of Jining Medical University

关键词 2型糖尿病艾塞那肽甘精胰岛素肥胖 Type 2 diabetes mellitus Exenatide Insulin glargine Obesity

分类号 R587.1 [医药卫生—内分泌]

引文网络
相关文献

参考文献5

1Yang W, Lu J, Weng J, et al. Prevalence o diabetes among men and women in China[J]. N Engl J Med, 2010,362:1090- 1101.
2Horton ES, Silberman C, Davis KL, et al. Weight loss, glyce- mie control,and changes in cardiovascular biomarkers in pa- tients with type 2 diabetes receiving incretin therapies or in- sulin in a large cobort database[J]. Diabetes Care, 2010,33 1759-1765.
3Glass LC, Qu Y, Lenox S, et al. Effects of exenatide versus insulin analogues on weight change in subjects with type 2 di- abetesa pooled post-hoc analysis[J]. Curr Med Res Opin, 2008,24: 639-644.
4Weyer C,Bogardus C,Mott DM,et al. The natural history of insulin secretory dysfunction and insulin resistance in the pathogenesis of type 2 diabetes mellitus[J]. J Clin Invest, 1999,104:787-794.
5Robert J, Luc F, Don Johns, et al. Exenatide versus insulin glargine in patients with suboptimally controlled tyre 2 diabe- tes[J]. Ann Intern Med, 2005,143 : 559-569.